Poziotinib is a novel, oral quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors, as well as HER receptor mutations. This in turn can lead to inhibition of the proliferation of tumor cells that overexpress these receptors.
At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize novel and targeted pharmaceuticals for unmet medical needs while building value for our shareholders.Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.
At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize novel and targeted pharmaceuticals for unmet medical needs while building value for our shareholders.Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.
Services
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that has the potential to transform the company.
All of our employees are committed to accomplishing the Company's mission and living by our corporate values. At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize novel and targeted pharmaceuticals for unmet medical needs while building value for our shareholders.
Our Compliance and Ethics Program is a set of internal controls and standards that promote adherence to pharmaceutical industry statutes, regulations, and requirements of the federal health care programs with respect to the development, manufacturing, marketing and selling of products. We foster an environment that promotes the prevention, detection and resolution of any regulatory or ethical challenges.
Our business model focuses on building a portfolio of novel and targeted drugs, primarily in the field of oncology, through acquisition and partnerships, rather than through in-house drug discovery. We then bring those drugs through the development process and make them available to patients.
We establish strategic alliances with leading biotechnology and pharmaceutical companies, represented by the list below, to leverage their strengths, mitigate risk inherent in the drug development process, accelerate drug development timelines, and generate cash through milestones, royalties and ultimately direct sales.
We establish strategic alliances with leading biotechnology and pharmaceutical companies, represented by the list below, to leverage their strengths, mitigate risk inherent in the drug development process, accelerate drug development timelines, and generate cash through milestones, royalties and ultimately direct sales.
William Ashton is a former Fortune 100 senior executive with over 40 years' experience in the biotechnology and pharmaceutical business. Mr. Ashton has retired from an extensive career at Amgen Inc. While with Amgen he served in various positions including Vice President of U.S. Sales for Amgen. He also served as Vice President/General Manager of the Corporate Accounts, Business Unit.
Reviews
Be the first to review Spectrum Pharmaceuticals.
Write a Review
